SS-31 (Elamipretide) · Research brief

SS-31 Elamipretide Trial July 2026: Half-Life and Status

Real Peptides Research TeamEditorial

Updated September 22, 20269 min read

41 WORDS

Short answer

Key takeaways

Elamipretide (SS-31) is a cationic tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2, of roughly 640 daltons, and its plasma half-life after subcutaneous administration is measured in hours rather than days.
SS-31 accumulates in the inner mitochondrial membrane by binding cardiolipin directly, a process reported to be largely independent of mitochondrial membrane potential.
The antioxidant effect attributed to SS-31 appears downstream of its disruption of the cytochrome c-cardiolipin peroxidase complex, not as a primary radical-scavenging action.
Barth syndrome, caused by TAZ gene mutations affecting tafazzin and cardiolipin remodelling, is the indication where the mechanism and the disease defect align most directly.
MMPOWER-3 in primary mitochondrial myopathy and ReCLAIM-2 in geographic atrophy both missed their primary endpoints, which is essential context for any ss-31 elamipretide trial july 2026 literature review.
Plasma concentration is a delivery measurement, not a target-engagement measurement; functional mitochondrial readouts are required to assess effect.

The most frequently quoted number about SS-31 is also the one most likely to wreck a study design. Elamipretide leaves plasma in hours, not days, yet the functional changes reported in mitochondrial preparations outlast measurable circulating peptide by a wide margin. Anyone chasing an ss-31 elamipretide trial july 2026 update is really chasing two separate facts that keep getting collapsed into one: the pharmacokinetic profile, and where the clinical programs actually stand.

We supply research-grade elamipretide to laboratories, and the question our team fields most often isn't about sequence verification or purity. It's why the published half-life looks so short next to the effects described in tissue. That gap is the entire story.

SS-31 elamipretide trial july 2026: what is the current status and half-life?

Elamipretide (SS-31) is a water-soluble cationic tetrapeptide of roughly 640 daltons with a short plasma half-life measured in hours after subcutaneous administration in clinical pharmacokinetic work. Its trial pipeline has concentrated on Barth syndrome, primary mitochondrial myopathy, and geographic atrophy secondary to dry age-related macular degeneration. Live registry status should be confirmed on ClinicalTrials.gov.

The common oversimplification is that a short half-life means a short duration of action. For elamipretide that inference collapses, because residence time in the inner mitochondrial membrane is governed by cardiolipin binding, not by plasma clearance. This article covers the measured pharmacokinetic profile, the cardiolipin mechanism that decouples exposure from effect, and the indication-by-indication trial record as it reads in 2026.

What the pharmacokinetic data actually says about half-life

Elamipretide is a four-residue peptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine, an unnatural aromatic amino acid. That alternating aromatic-cationic motif gives the molecule a net positive charge at physiological pH and is the structural reason it partitions into anionic lipid membranes. Reported clinical pharmacokinetics describe rapid absorption after subcutaneous administration with peak plasma concentration reached within roughly an hour, followed by a short terminal phase consistent with peptidase cleavage and renal elimination of a small peptide.

So when researchers search for ss-31 elamipretide half-life pharmacokinetics, the number they find is describing the circulating compartment only. Plasma area under the curve tells you about delivery. It does not tell you about target occupancy.

There is a second point about ss-31 elamipretide half-life that most summaries skip entirely. Unlike triphenylphosphonium-conjugated mitochondrial agents such as MitoQ, which accumulate in proportion to mitochondrial membrane potential, SS-31 uptake into the inner membrane is reported to be largely potential-independent. It associates with cardiolipin directly. In practical terms, that means the peptide can still reach its binding partner in depolarised or dysfunctional mitochondria, which is precisely the population of organelles most disease models are built around.

In our experience fielding technical questions from laboratories working with this compound, the ss-31 elamipretide trial july 2026 literature is misread in the same way every time: teams assume a short plasma half-life means the compound must be gone. Clearance and target disengagement are not the same event.

Cardiolipin binding: the mechanism that separates exposure from effect

Cardiolipin is the signature phospholipid of the inner mitochondrial membrane, unusual because it carries four acyl chains rather than two. That geometry drives the negative curvature required for cristae folding, and cardiolipin is required for stable assembly of electron transport chain supercomplexes, the physical clustering of complexes I, III and IV that makes electron transfer efficient.

SS-31 associates with cardiolipin through combined electrostatic and hydrophobic interaction. Two downstream consequences follow. Cristae architecture is stabilised, which supports supercomplex assembly and ATP synthesis. And the cytochrome c-cardiolipin peroxidase complex, which converts cytochrome c into a lipid-peroxidising enzyme, is disrupted, limiting cardiolipin peroxidation and the reactive oxygen species cascade that follows.

That ordering matters. SS-31 is routinely labelled an antioxidant peptide, but the antioxidant effect reads as downstream of a lipid-interaction event, not as the primary action. It is a membrane-remodelling agent first.

This is also why Barth syndrome became the lead indication. Barth syndrome is caused by mutations in the TAZ gene encoding tafazzin, the acyltransferase responsible for cardiolipin remodelling. Patients accumulate monolysocardiolipin and lose mature tetralinoleoyl cardiolipin. A compound whose mechanism is cardiolipin stabilisation maps onto that defect more directly than onto almost any other condition.

Here is the mistake we see most often in study design, and it isn't the reconstitution step. It's treating plasma concentration as the target-engagement readout. If the binding partner sits inside the inner mitochondrial membrane, the meaningful measurements are functional: phosphocreatine recovery kinetics by 31P magnetic resonance spectroscopy, cristae morphology on electron microscopy, supercomplex assembly by blue native PAGE, or respirometry on isolated mitochondria. Plasma tells you the peptide arrived. Nothing more.

Where the clinical programs stand in 2026

The honest summary of the ss-31 elamipretide trial july 2026 picture is that one narrow indication advanced and the broader ones have been difficult. In Barth syndrome, the TAZPOWER crossover study did not meet its primary endpoints during the blinded phase, but the open-label extension reported improvement in six-minute walk distance that persisted over extended follow-up. Regulatory review of that package was contentious, the decision date moved more than once, and public records indicate elamipretide ultimately reached the market for Barth syndrome under a narrow accelerated approval pathway. Current labelling should be confirmed through FDA resources rather than secondary coverage.

MMPOWER-3, the Phase 3 study in primary mitochondrial myopathy, did not meet its co-primary endpoints of six-minute walk distance and patient-reported fatigue at 24 weeks. In ophthalmology, the Phase 2 ReCLAIM-2 study in geographic atrophy missed its primary low-luminance visual acuity endpoint while reporting a signal on lesion growth, and the ReNEW and ReGAIN Phase 3 programs followed from that. An earlier cardiology study in acute reperfusion injury, EMBRACE-STEMI, did not reduce infarct size.

Notice the pattern. Where cardiolipin biology is genetically broken, the effect is detectable. Where mitochondrial dysfunction is heterogeneous or secondary, it has been much harder to demonstrate.

The information here is educational and describes published research. Material we supply is research-use-only, not a drug product for human or veterinary administration, and anyone with a question about animal health should talk to their veterinarian.

SS-31 Elamipretide Trial July 2026: Indication-by-Indication Comparison

This table maps each major elamipretide program against its reported endpoint outcome, which is the fastest way to see why the compound's reputation varies so much by field. Use it to calibrate which disease models the published evidence actually supports.

Indication	Lead study or program	Reported endpoint outcome	Bottom Line for Researchers
Barth syndrome (TAZ mutation)	TAZPOWER and its open-label extension	Blinded phase missed primary endpoints; extension reported sustained six-minute walk improvement	Strongest mechanism-to-disease match, since the defect is cardiolipin remodelling itself; the most defensible model for translational work
Primary mitochondrial myopathy	MMPOWER-3 (Phase 3)	Co-primary endpoints of walk distance and fatigue not met at 24 weeks	A heterogeneous genetic population diluted any signal; treat pooled myopathy models with caution in study design
Geographic atrophy, dry AMD	ReCLAIM-2 (Phase 2), ReNEW and ReGAIN (Phase 3)	Primary low-luminance visual acuity endpoint not met; lesion growth signal reported	Retinal pigment epithelium is mitochondria-dense, making it mechanistically plausible; confirm current Phase 3 status on the registry before citing
Acute reperfusion injury	EMBRACE-STEMI	No reduction in infarct size	Single-dose acute protection did not translate; short plasma exposure is a plausible contributor
Heart failure and renal models	Early-phase and preclinical work	Mixed exploratory findings, no confirmatory readout	Useful preclinical context only; not a basis for efficacy claims of any kind

What If: SS-31 Research Scenarios

What if my lyophilised elamipretide sat at ambient temperature during shipping?

Document the excursion, then verify identity and purity against the batch certificate before using the material in any quantitative work. Lyophilised peptides are considerably more stable than solutions, and short ambient exposure during transit is common, but a cationic tetrapeptide in solution is far more vulnerable to degradation. Laboratories that log temperature history and cross-check against mass spectrometry data on the certificate avoid attributing a handling failure to a biological result.

What if plasma levels are undetectable but I still see an effect in tissue?

That dissociation is expected rather than anomalous, and it should be reported rather than explained away. The short ss-31 elamipretide half life reflects clearance from circulation, while the pharmacodynamic effect depends on peptide already partitioned into the inner mitochondrial membrane and bound to cardiolipin. Designing around plasma sampling alone will systematically under-describe what the compound is doing.

What if MMPOWER-3 missed its endpoints? Does that invalidate the mechanism?

No, but it should reshape which models you choose. Primary mitochondrial myopathy encompasses many different nuclear and mitochondrial DNA mutations with different biochemical consequences, so a single cardiolipin-directed intervention may benefit a subset while the pooled population shows no significant change. A negative Phase 3 result in a heterogeneous population is weak evidence against a mechanism that a genetically defined population supported.

What if I can't find a current readout for the indication I'm studying?

Go to the ClinicalTrials.gov registry entry and read the posted status and results fields directly rather than relying on press coverage. Trial status changes without announcement, completion dates shift, and the ss-31 elamipretide trial july 2026 search results are dominated by older secondary summaries that quietly go stale. Registry records and peer-reviewed publications are the only two sources worth citing in a protocol.

The unglamorous truth about a short half-life

Let's be direct about this: the half-life figure people quote for SS-31 is real, correctly measured, and almost useless on its own. It describes how fast a small cationic peptide leaves blood, which is a question about kidneys and peptidases, not about mitochondria. The number that would actually predict effect, residence time on cardiolipin in the inner membrane, is far harder to measure and far less often reported. Treating the plasma value as the duration of action is the single most common error in the ss-31 elamipretide trial july 2026 discussion, and it leads directly to underpowered sampling schedules and misread negative results.

Laboratories sourcing material for this work can review batch documentation on our SS-31 (elamipretide) research peptide listing, while our SS-31 research overview collects the mechanism and pharmacokinetic literature in one place. Third-party purity and mass spectrometry reports are archived in our certificates of analysis library, the broader research peptide catalog is organised by target pathway, and handling and fulfilment details are set out on our facility page.

Anyone still hoping the ss-31 elamipretide trial july 2026 record contains a breakthrough will find something less dramatic and more instructive: a compound with an unusually well-defined molecular target, a plasma half-life that means far less than it appears to, and a clinical history that advanced in the one population whose genetic defect maps directly onto the mechanism. That last detail is the real lesson. SS-31 performs where cardiolipin biology is already broken. Match the model to the mechanism, and the data stops looking contradictory.

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138

Questions

Published clinical pharmacokinetic work describes elamipretide as having a short plasma half-life measured in hours rather than days after subcutaneous administration, with peak plasma concentration reached within roughly an hour. This is typical for a small cationic tetrapeptide subject to peptidase cleavage and renal elimination. The plasma figure describes clearance from circulation only and does not describe how long the peptide remains bound to cardiolipin in the inner mitochondrial membrane.

As of 2026, the elamipretide pipeline centres on Barth syndrome, primary mitochondrial myopathy and geographic atrophy in dry age-related macular degeneration. Public regulatory records indicate the compound reached the market for Barth syndrome through a narrow accelerated approval pathway, while MMPOWER-3 in primary mitochondrial myopathy and the Phase 2 ReCLAIM-2 study in geographic atrophy both missed their primary endpoints. Registry entries on ClinicalTrials.gov are the authoritative source for live status.

SS-31 is a cationic aromatic tetrapeptide that associates directly with cardiolipin, the four-acyl-chain phospholipid concentrated in the inner mitochondrial membrane. Unlike triphenylphosphonium-conjugated mitochondrial agents such as MitoQ, whose accumulation scales with mitochondrial membrane potential, SS-31 uptake is reported to be largely potential-independent. That distinction matters because it means the peptide can still reach its binding partner in depolarised or dysfunctional mitochondria.

Because clearance from blood and disengagement from the target are separate events. Once elamipretide has partitioned into the inner mitochondrial membrane and bound cardiolipin, its effects on cristae architecture, electron transport chain supercomplex assembly and cardiolipin peroxidation persist independently of circulating concentration. This is why plasma area under the curve is a poor surrogate for pharmacodynamic effect in SS-31 studies.

No. Research-grade elamipretide supplied by Real Peptides is a research-use-only material intended for laboratory investigation, not a drug product and not for human or veterinary administration. A narrow accelerated approval exists for one ultra-rare genetic condition, which is a regulated prescription context entirely separate from research chemical supply. Questions about animal health should be directed to a licensed veterinarian.

Pricing varies widely by vial quantity, synthesis scale and the depth of analytical documentation provided with the batch. The meaningful cost comparison is not price per milligram but price per verified milligram, since purity, peptide content and correct sequence confirmation determine whether a batch is usable for quantitative work. Always check that HPLC purity and mass spectrometry data are available before comparing suppliers on price alone.

Standard laboratory practice for lyophilised research peptides is storage in a freezer, protected from light and moisture, with the vial allowed to reach room temperature before opening to prevent condensation. Once a peptide is in solution it is considerably less stable than the lyophilised powder, so solutions are typically kept refrigerated and aliquoted to avoid repeated freeze-thaw cycles. Any temperature excursion should be logged against the batch record.

MitoQ is a ubiquinone conjugated to a lipophilic triphenylphosphonium cation, so it accumulates in proportion to mitochondrial membrane potential and acts primarily as a redox-cycling antioxidant. SS-31 works differently: it binds cardiolipin, stabilising cristae curvature and supercomplex assembly, with reduced reactive oxygen species appearing as a downstream consequence rather than the primary action. In depolarised mitochondria, potential-dependent accumulation falls away while cardiolipin binding does not.

MMPOWER-3 enrolled patients with primary mitochondrial myopathy, a category covering many distinct nuclear and mitochondrial DNA mutations with different biochemical consequences. Its co-primary endpoints, six-minute walk distance and patient-reported fatigue, were not met at 24 weeks. A plausible interpretation is that a cardiolipin-directed intervention may benefit a genetically defined subset while showing no significant effect across a pooled, heterogeneous population.

The Phase 2 ReCLAIM-2 study did not meet its primary low-luminance visual acuity endpoint but reported a signal on geographic atrophy lesion growth, which is what supported continuation into the ReNEW and ReGAIN Phase 3 programs. The retinal pigment epithelium is one of the most mitochondria-dense tissues in the body, which makes the mechanism plausible in principle. Confirm current Phase 3 status and any posted results on ClinicalTrials.gov before citing the program.

Barth syndrome is caused by mutations in the TAZ gene encoding tafazzin, the acyltransferase that remodels immature cardiolipin into its mature tetralinoleoyl form. Patients accumulate monolysocardiolipin and lose functional cardiolipin, which destabilises cristae and electron transport chain supercomplexes. Since SS-31 acts by binding and stabilising cardiolipin, the mechanism maps onto the genetic defect more directly than onto any other condition studied so far.

Because the binding partner sits inside the inner mitochondrial membrane, target engagement has to be inferred from function rather than circulating concentration. Commonly used readouts include phosphocreatine recovery kinetics by 31P magnetic resonance spectroscopy, cristae morphology assessed by electron microscopy, supercomplex assembly by blue native PAGE, and oxygen consumption measured by respirometry on isolated mitochondria. Plasma sampling confirms delivery, not occupancy.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA